Pantoprazole A Proton Pump Inhibitor

被引:21
作者
Dias, Luis Moreira
机构
[1] Médico Gastroenterologista,
关键词
GASTROESOPHAGEAL-REFLUX DISEASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; A BLOOD-CONCENTRATION; 40 MG PANTOPRAZOLE; MAINTENANCE THERAPY; DOUBLE-BLIND; PHARMACOKINETIC INTERACTION; GASTROINTESTINAL LESIONS; EROSIVE ESOPHAGITIS; ORAL PANTOPRAZOLE;
D O I
10.2165/1153121-S0-000000000-00000
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pantoprazole is a proton pump inhibitor (PPI) that binds irreversibly and specifically to the proton pump, thereby reducing gastric acid secretion. Pantoprazole has a relatively long duration of action compared with other PPIs, and a lower propensity to become activated in slightly acidic body compartments. To date, no drug-drug interactions have been identified with pantoprazole in numerous interaction Studies. Overall, in the short-term (8-10 weeks) initial treatment of gastro-oesophageal reflux disease (a condition that occurs when the reflux of gastric contents causes troublesome symptoms and/or complications) and long-term (6-24 months) maintenance therapy, oral pantoprazole 20 or 40 mg/day demonstrated similar efficacy to omeprazole, lansoprazole and esomeprazole and greater efficacy than histamine type 2 receptor antagonists. Pantoprazole is also effective in treating and preventing NSAID-related gastric and gastroduodenal injury. The optimal adult oral dose for gastric acid-related disorders is pantoprazole 40 mg once daily. Although data are limited, pantoprazole 20 or 40 mg/day was effective and well tolerated in the treatment of acid-related disorders in children and adolescents. Pantoprazole was also well tolerated in adults With acid-related disorders in short- and long-term Studies. Thus, pantoprazole is a valuable agent for the management of acid-related disorders.
引用
收藏
页码:3 / 12
页数:10
相关论文
共 54 条
[1]  
[Anonymous], 2002, Cochrane Database Syst Rev, DOI 10.1002/14651858.CD002296
[2]   A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease [J].
Bardhan, K. D. ;
Achim, A. ;
Riddermann, T. ;
Pfaffenberger, B. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (12) :1461-1469
[3]   Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis [J].
Bardhan, KD ;
Van Rensburg, C .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (10) :1585-1591
[4]  
Berardi RR, 2000, AM J MANAG CARE, V6, pS491
[5]   Pharmacokinetic drug interaction profiles of proton pump inhibitors [J].
Blume, Henning ;
Donath, Frank ;
Warnke, Andre ;
Schug, Barbara S. .
DRUG SAFETY, 2006, 29 (09) :769-784
[6]   Guide to the use of Proton Pump Inhibitors in adult patients [J].
Boparai, Vandana ;
Rajagopalan, Jaishree ;
Triadafilopoulos, George .
DRUGS, 2008, 68 (07) :925-947
[7]   Prevention of the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs the role of proton pump inhibitors [J].
Brown, GJE ;
Yeomans, ND .
DRUG SAFETY, 1999, 21 (06) :503-512
[8]   Pantoprazole - An update of its pharmacological properties and therapeutic use in the management of acid-related disorders [J].
Cheer, SM ;
Prakash, A ;
Faulds, D ;
Lamb, HM .
DRUGS, 2003, 63 (01) :101-132
[9]   Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis [J].
Chiba, N ;
DeGara, CJ ;
Wilkinson, JM ;
Hunt, RH .
GASTROENTEROLOGY, 1997, 112 (06) :1798-1810
[10]   The role of proton pump inhibitors in gastro-oesophageal reflux disease [J].
Dekel, R ;
Morse, C ;
Fass, R .
DRUGS, 2004, 64 (03) :277-295